A Randomised, Open-label Four-way Crossover Study to Evaluate Relative Bioavailability of Tiotropium and Salmeterol After Inhalation of a Fixed Combined Single Dose (7.5 μg Tiotropium, 25 μg Salmeterol, Inhalation Powder, Hard Capsule, HandiHaler2), a Free Combined Single Dose of 18 μg Tiotropium [Spiriva HandiHaler] and 50 μg Salmeterol [Serevent Diskus], a Single Dose of 50μg Salmeterol (Serevent Diskus) and a Single Dose of 18 μg Tiotropium (Spiriva HandiHaler) in Healthy Male Volunteers

Trial Profile

A Randomised, Open-label Four-way Crossover Study to Evaluate Relative Bioavailability of Tiotropium and Salmeterol After Inhalation of a Fixed Combined Single Dose (7.5 μg Tiotropium, 25 μg Salmeterol, Inhalation Powder, Hard Capsule, HandiHaler2), a Free Combined Single Dose of 18 μg Tiotropium [Spiriva HandiHaler] and 50 μg Salmeterol [Serevent Diskus], a Single Dose of 50μg Salmeterol (Serevent Diskus) and a Single Dose of 18 μg Tiotropium (Spiriva HandiHaler) in Healthy Male Volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 09 Oct 2014

At a glance

  • Drugs Salmeterol/tiotropium bromide (Primary) ; Salmeterol; Tiotropium bromide
  • Indications Chronic obstructive pulmonary disease
  • Focus Pharmacokinetics
  • Sponsors Boehringer Ingelheim
  • Most Recent Events

    • 09 Oct 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top